 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C36H44N4O4S |
| Molecular Weight | 628.82 |
| Exact Mass | 628.308 |
| CAS # | 2881068-33-1 |
| PubChem CID | 164887546 |
| Appearance | Typically exists as solid at room temperature |
| LogP | 7.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 45 |
| Complexity | 905 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | IGQZWUKVEBOWDQ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C36H44N4O4S/c1-5-26-22-28(39-17-11-8-12-18-39)23-27(6-2)40(26)36(41)44-34-29(42-3)20-25(21-30(34)43-4)35-37-32(24-14-9-7-10-15-24)33(38-35)31-16-13-19-45-31/h7,9-10,13-16,19-21,26-28H,5-6,8,11-12,17-18,22-23H2,1-4H3,(H,37,38) |
| Chemical Name | [2,6-dimethoxy-4-(4-phenyl-5-thiophen-2-yl-1H-imidazol-2-yl)phenyl] 2,6-diethyl-4-piperidin-1-ylpiperidine-1-carboxylate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | nSMase2[1] |
| ln Vitro | After one hour at 37 °C, >75% of the intact prodrug in DPTIP-prodrug 18 remained, indicating that it is metabolically stable[1]. |
| ln Vivo | An outstanding PK profile is shown by DPTIP-prodrug 18[1]. Significant suppression of nSMase2 activity and IL-1β-induced EV release in mice is demonstrated by DPTIP-prodrug 18[1]. |
| Animal Protocol |
Animal/Disease Models: CES1–/– mice[1] Doses: 10 mg/kg DPTIP equivalent Route of Administration: Orally, once (pharmacokinetic/PK Analysis) Experimental Results: demonstrated >fourfold higher plasma (AUC0-t=1047 pmol·h/mL) and brain exposures (AUC0-t=247 pmol·h/g) versus DPTIP and a significant enhancement of DPTIP half-life (2 h vs ~0.5 h). Animal/Disease Models: Interleukin-1β-injected mice (a mouse model of brain injury)[1] Doses: 0, 3 and 10 mg/kg ( DPTIP equivalent) Route of Administration: Orally, once Experimental Results: Dramatically inhibited the release of brain-derived GFP+ EVs into the blood at both 3 and 10 mg/kg (DPTIP equivalent dose). |
| References |
[1]. Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP. J Med Chem. 2022 Aug 5. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5903 mL | 7.9514 mL | 15.9028 mL | |
| 5 mM | 0.3181 mL | 1.5903 mL | 3.1806 mL | |
| 10 mM | 0.1590 mL | 0.7951 mL | 1.5903 mL |